Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market 2019 by Company, Regions, Type and Application, Forecast to 2024
June 2019
139
About the Report
About the Report
Scope of the Report:
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drug EGFR RTK Inhibitors for NSCLC.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Targeted Drug EGFR RTK Inhibitors for NSCLC market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type and applications/end industries.
Market Segment by Companies, this report covers
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Other
Market Segment by Applications, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Products
Companies
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Table of Contents
Table of Contents
Table of Contents
1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug EGFR RTK Inhibitors for NSCLC
1.2 Classification of Targeted Drug EGFR RTK Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Comparison by Types (2019-2024)
1.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Icotinib
1.2.4 Gefitinib
1.2.5 Erlotinib
1.2.6 Afatinib
1.2.7 Osimertinib
1.2.8 Brigatinib
1.2.9 Other
1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2014-2024)
1.5 Global Market Size of Targeted Drug EGFR RTK Inhibitors for NSCLC (2014-2024)
2 Manufacturers Profiles
2.1 Beta Pharma
2.1.1 Business Overview
2.1.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.2 AstraZeneca
2.2.1 Business Overview
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.4 Qilu Pharmaceutical
2.4.1 Business Overview
2.4.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.5 Genentech (Roche Group)
2.5.1 Business Overview
2.5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.6 Mylan
2.6.1 Business Overview
2.6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.7 Teva
2.7.1 Business Overview
2.7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.8 OSI Pharmaceuticals
2.8.1 Business Overview
2.8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.9 Glenmark Pharmaceuticals
2.9.1 Business Overview
2.9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.10 Beacon Pharmaceuticals
2.10.1 Business Overview
2.10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.11 Boehringer Ingelheim
2.11.1 Business Overview
2.11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.12 Pfizer
2.12.1 Business Overview
2.12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.13 ARIAD Pharmaceuticals (Takeda)
2.13.1 Business Overview
2.13.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.14 Genvio Pharma Limited
2.14.1 Business Overview
2.14.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.15 Drug International Limted
2.15.1 Business Overview
2.15.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.16 Everest Pharmaceuticals
2.16.1 Business Overview
2.16.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.17 Incepta Pharmaceuticals Limited
2.17.1 Business Overview
2.17.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.18 Cipla Pharma
2.18.1 Business Overview
2.18.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.19 Dr Reddy's Laboratories
2.19.1 Business Overview
2.19.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.20 Zydus Cadila
2.20.1 Business Overview
2.20.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.21 Hetero Drugs
2.21.1 Business Overview
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.22 Intas Pharmaceuticals
2.22.1 Business Overview
2.22.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.23 Alkem Laboratories
2.23.1 Business Overview
2.23.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.24 RPG Life Sciences
2.24.1 Business Overview
2.24.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.25 Fresenius Kabi India
2.25.1 Business Overview
2.25.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.5 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
5.2 USA Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.3 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.4 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
6.2 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.3 UK Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.4 France Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.5 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.6 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
7.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.4 Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.5 India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
8.2 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.3 Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.4 Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Targeted Drug EGFR RTK Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
9.2 Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.3 UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.4 Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.5 Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.6 South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
10 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)
10.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Type (2019-2024)
10.3 Icotinib Revenue Growth Rate (2014-2024)
10.4 Gefitinib Revenue Growth Rate (2014-2024)
10.5 Erlotinib Revenue Growth Rate (2014-2024)
10.6 Afatinib Revenue Growth Rate (2014-2024)
10.7 Osimertinib Revenue Growth Rate (2014-2024)
10.8 Brigatinib Revenue Growth Rate (2014-2024)
10.9 Other Revenue Growth Rate (2014-2024)
11 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)
11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Application (2019-2024)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
12 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast (2019-2024)
12.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast (2019-2024)
12.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Regions (2019-2024)
12.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.6 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Table
List of Tables and Figures
Figure Targeted Drug EGFR RTK Inhibitors for NSCLC Picture
Table Product Specifications of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC and Revenue (Million USD) Market Split by Product Type
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Types in 2018
Figure Icotinib Picture
Figure Gefitinib Picture
Figure Erlotinib Picture
Figure Afatinib Picture
Figure Osimertinib Picture
Figure Brigatinib Picture
Figure Other Picture
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Application (2014-2024)
Figure Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Applications in 2018
Figure Squamous Cell Carcinoma of NSCLC Picture
Figure Adenocarcinoma of NSCLC Picture
Figure Large Cell Carcinoma of NSCLC Picture
Table Global Market Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Table Beta Pharma Basic Information, Manufacturing Base and Competitors
Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table AstraZeneca Basic Information, Manufacturing Base and Competitors
Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Natco Pharma Basic Information, Manufacturing Base and Competitors
Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Genentech (Roche Group) Basic Information, Manufacturing Base and Competitors
Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Mylan Basic Information, Manufacturing Base and Competitors
Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Teva Basic Information, Manufacturing Base and Competitors
Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table OSI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Glenmark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Beacon Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table ARIAD Pharmaceuticals (Takeda) Basic Information, Manufacturing Base and Competitors
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Genvio Pharma Limited Basic Information, Manufacturing Base and Competitors
Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Drug International Limted Basic Information, Manufacturing Base and Competitors
Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Everest Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Incepta Pharmaceuticals Limited Basic Information, Manufacturing Base and Competitors
Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Cipla Pharma Basic Information, Manufacturing Base and Competitors
Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Dr Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Zydus Cadila Basic Information, Manufacturing Base and Competitors
Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Hetero Drugs Basic Information, Manufacturing Base and Competitors
Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Alkem Laboratories Basic Information, Manufacturing Base and Competitors
Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table RPG Life Sciences Basic Information, Manufacturing Base and Competitors
Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Fresenius Kabi India Basic Information, Manufacturing Base and Competitors
Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Players (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players in 2017
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players in 2018
Figure Global Top 5 Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share in 2018
Figure Global Top 10 Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share in 2018
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Regions (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Regions in 2018
Figure North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
Table North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure USA Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Figure Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure UK Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure France Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2014-2019)
Table South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) by Type (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Type (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Type (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Type in 2018
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Forecast by Type (2019-2024)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share Forecast by Type (2019-2024)
Figure Global Icotinib Revenue Growth Rate (2014-2019)
Figure Global Gefitinib Revenue Growth Rate (2014-2019)
Figure Global Erlotinib Revenue Growth Rate (2014-2019)
Figure Global Afatinib Revenue Growth Rate (2014-2019)
Figure Global Osimertinib Revenue Growth Rate (2014-2019)
Figure Global Brigatinib Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2014-2019)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Application (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Application (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Application in 2018
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Forecast by Application (2019-2024)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share Forecast by Application (2019-2024)
Figure Global Squamous Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Adenocarcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Large Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.